Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
US venture capital investment in biotechnology companies fell during the second quarter, but remained near recent record-breaking levels as investors continued to support larger funding rounds for some biotechnology startups – a trend that's ongoing in the third quarter with Series A rounds totaling $57m for Oncorus Inc. and $55m for Fulcrum Therapeutics.
A hundred biotech companies raised $1.7bn during the second quarter of 2016 compared with 127 that raised $2.1bn during the...
Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.
Comes Days After PDUFA Pushback For GSK's Blenrep.
A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
Comes Days After PDUFA Pushback For GSK's Blenrep.
